Abstract
Inhibitors targeting cyclic nucleotide phosphodiesterases (PDEs) expressed in leukocytes have entered clinical practice to treat inflammatory disorders, with three PDE4 inhibitors currently in clinical use as therapeutics for psoriasis, psoriatic arthritis, atopic dermatitis and chronic obstructive pulmonary disease. In contrast, the PDE8 family that is upregulated in pro-inflammatory T cells is a largely unexplored therapeutic target. It was shown that PDE8A plays a major role in controlling T cell and breast cancer cell motility, including adhesion to endothelial cells under physiological shear stress and chemotaxis. This is a unique function of PDE8 not shared by PDE4, another cAMP specific PDE, employed, as noted, as an anti-inflammatory therapeutic. Additionally, a regulatory role was shown for the PDE8A-rapidly accelerated fibrosarcoma (Raf)-1 kinase signaling complex in myelin antigen reactive CD4+ effector T cell adhesion and locomotion by a mechanism differing from that of PDE4. The PDE8A-Raf-1 kinase signaling complex affects T cell motility, at least in part, via regulating the LFA-1 integrin mediated adhesion to ICAM-1. The findings that PDE8A and its isoforms are expressed at higher levels in naive and myelin oligodendrocyte glycoprotein (MOG)35–55 activated effector T (Teff) cells compared to regulatory T (Treg) cells and that PDE8 inhibition specifically affects MOG35–55 activated Teff cell adhesion, indicates that PDE8A could represent a new beneficial target expressed in pathogenic Teff cells in CNS inflammation. The implications of this work for targeting PDE8 in inflammation will be discussed in this review.
Introduction
With over 800 members identified in humans, G protein coupled receptors (GPCRs) constitute a large group of signaling molecules expressed on many cells. Together with their other associated signaling molecules, they are the targets for nearly 35% of approved therapeutics (Sriram and Insel, 2018). The majority of therapeutically targeted GPCRs affect the cAMP signaling pathway which is also a major target of potent anti-inflammatory drugs (Schett et al., 2010; Rabe, 2011; Tenor et al., 2011; De Souza et al., 2012; Milara et al., 2012; Schafer, 2012; Wittmann and Helliwell, 2013; Victoni et al., 2014; Dong et al., 2016; Jarnagin et al., 2016; Tom et al., 2016; Zane et al., 2016a, b; Sriram and Insel, 2018; ). cAMP is involved in many physiological functions and a well-established key regulator of chemotaxis and inflammation (Bourne et al., 1974; ). Binding of extracellular ligands such as chemokines to Gs-coupled GPCRs leads to cAMP synthesis via activation of adenylyl cyclase and conversion of ATP to cAMP (Weis and Kobilka, 2018). Additionally, T cell activation leads to a temporary upregulation of cAMP which is then degraded by cyclic nucleotide phosphodiesterase (PDE) enzymes (Wang et al., 1978). PDEs constitute the sole group of molecules known to hydrolyze cAMP and hence maintain spatial and temporal control over cAMP gradients within a cell (). PDEs are grouped into 11 different gene families considering their action on cAMP or cGMP, structural similarity and mode of regulation (Lerner and Epstein, 2006). While PDEs had been considered early as good targets for anti-inflammatory drugs, bringing specific PDE inhibitors into clinical use has faced decades of challenges (Francis et al., 2011), mostly because of off target effects including emesis (Giembycz, 2000; ). The approval of small molecule inhibitors of PDE4 to treat major immunologic conditions demonstrates a tremendous progress over the last 7 years with indications expanding at an almost yearly pace (Maurice et al., 2014; ). Current clinical practice includes several small molecule compounds that target PDE4 for the therapy of lung disease (COPD) (Hatzelmann et al., 2010; Weis and Kobilka, 2018), psoriatic arthritis and plaque psoriasis (Schett et al., 2012) and topically for atopic dermatitis (Callender et al., 2019). Hence PDE inhibitors are proving to be of great clinical benefit in inflammatory disorders (). This review will focus on the selective and shared roles of PDE isoforms during the regulation of T cell motility with emphasis on novel insights of PDE8 functions.
PDE Expression in Immune Cells
As shown in Table 1 [adapted from Lerner and Epstein (2006)], PDEs are encoded by twenty one genes and are by convention organized into 11 gene families based on their key properties. These include overlap in sequence, specificity for cAMP or cGMP as substrate and their mode of regulation. With alternative splicing as well as the existence of multiple transcription initiation sites, at least 100 different forms of PDE have been cloned and many are expressed in a cell and tissue selective manner. Among the 11 PDE gene families, PDE4, PDE7, and PDE8 selectively hydrolyze cAMP as substrate and degrade it into 5′-AMP, PDE5, PDE6, and PDE9 selectively hydrolyze cGMP as substrate, and PDE1, PDE2, PDE3, PDE10, and PDE11 hydrolyze both cAMP and cGMP as substrate. Of note, the affinity of PDE8 for cAMP is greater than that of any of the other PDE gene families (Fisher et al., 1998a; Hayashi et al., 1998; Soderling et al., 1998a; Gamanuma et al., 2003; ).
TABLE 1
Pde gene families.
1Shown in this table [adapted from Lerner and Epstein (2006)] are the eleven PDE gene families, the known genes within them, their affinity constants for cAMP and cGMP, and commonly used pharmacological inhibitors for each of the families. The substrate affinity constants listed are approximate and where ranges are given, they represent the range of different Kms reported for these family members in the references cited. 2The numbers in parentheses are the approximate reported Kis or IC50s for inhibition of that PDE gene family, given in μM. Note: the non-specific methylxanthine inhibitor IBMX inhibits all of the PDE families with the notable exception of the PDE8 and PDE9 gene families, which appear to be resistant to IBMX inhibition.
PDE4
Early studies showed PDE4 to be the predominant form of PDE expressed in the cytosolic fraction of human lymphocytes (Epstein and Hachisu, 1984), with PDE4A, 4B, and 4D, but not 4C being expressed (Jiang et al., 1998). PDE4 has long been known to play a key role in regulating T cell activation and functions (Michie et al., 1996; Ekholm et al., 1997; Erdogan and Houslay, 1997; Gantner et al., 1997a, b; Sommer et al., 1997; ; Jin et al., 1998, 2010; ; Hatzelmann and Schudt, 2001; Kanda and Watanabe, 2001; ; ; ; Claveau et al., 2004; Jimenez et al., 2004; ; Peter et al., 2007; , ; Vang et al., 2016). A key mechanism appears to be the modulation of signal transduction through the T cell receptor (TCR). Activation of the TCR leads to cAMP production localized in lipid rafts, activation of cAMP dependent protein kinase A (PKA) and subsequent inhibition of the TCR signal (; ; Wehbi and Tasken, 2016; Figure 1). However, engagement of the co-stimulatory receptor CD28 leads to the recruitment of beta-arrestin and PDE4 to lipid rafts and the decrease of the local cAMP pool and PKA activity. PDE4 inhibitors downregulate the TCR signal by increasing local cAMP concentrations and PKA activity and counteract the CD28-induced recruitment of PDE4. Thus, localized activities of cAMP, PKA, and PDE4 regulate the upstream TCR signal necessary for T cell activation and the subsequent initiation of effector functions.
FIGURE 1
PDE3
PDE3 was found to be the predominant form expressed in particulate fractions of human lymphocytes, solely as PDE3B (Tenor et al., 1995; Ekholm et al., 1997; Sheth et al., 1997). In contrast, PDE3B expression is low in regulatory T(reg) cells, and it appears that the low catalytic activity of PDE3B is critical for the regulation of Treg cell-specific gene expression (Gavin et al., 2007). When PDE expression profiles of human T and B lymphocytes were compared, it is of note that in contrast to T cells, which expressed high amounts of PDE3, B cells expressed little or no PDE3 (Gantner et al., 1998).
PDE7
PDE7, primarily PDE7A, was also found to be expressed in human lymphocytes, to a lesser extent than PDE3 and PDE4, with PDE7A1 primarily cytosolic and PDE7A2 mainly associated with a particulate fraction (; Giembycz et al., 1996; ). Subsequent studies also showed that PDE1B, PDE7A, and PDE8A were all induced following activation of human lymphocytes (Epstein et al., 1980, 1987; Jiang et al., 1998; Glavas et al., 2001; Kanda and Watanabe, 2001). A critical role of the induction of PDE7 for a full T cell activation has been reported (Li et al., 1999; Guo et al., 2009; Szczypka, 2020). Inhibition studies using PDE7 selective inhibitors have yielded divergent results and seem to point to a context and other PDE isoform dependent role of PDE7 in T cell functions and T cell mediated inflammation (Li et al., 1999; Nakata et al., 2002; Yang et al., 2003; Nueda et al., 2006; Goto et al., 2009; Guo et al., 2009; Kadoshima-Yamaoka et al., 2009; Redondo et al., 2012; Gonzalez-Garcia et al., 2013; Xu et al., 2016; Martin-Alvarez et al., 2017; Szczypka, 2020).
PDE8
The expression of PDE8 in immune cells is listed in Table 2. The function of PDE8 in T cells and cancer cells is discussed in detail below.
TABLE 2
| Immune cell subpopulation | PDE gene expression | PDE protein expression | Results | References |
| CD4+ T cells | PDE8A1 | PDE8A1 | Upregulation of PDE8A1 after polyclonal T cell activation | Glavas et al., 2001 |
| Mitogen-activated splenocytes, anti-CD3 activated CD4+ T cells | PDE8A | Induction of PDE8A expression in response to stimulus | Dong et al., 2006; Vang et al., 2010 | |
| Antigen exposed naïve and memory CD4+ T cells | PDE8A | Changes in temporal expression patterns in response to antigen challenge | Vang et al., 2010 | |
| CD4+ T cells | PDE8A | PDE8A | Association of PDE8A expression and accumulation of sensitized T cells in draining lymph node of in an animal model of allergic airway disease (AAD) | Vang et al., 2016 |
| CD4– T cells | Low PDE8A | Low PDE8A | Control cell population in AAD | Vang et al., 2016 |
| CD4+ T cells | High PDE8A | High PDE8A | Hilar lymph node in AAD | Vang et al., 2016 |
| CD4+ effector T(eff) cells | Increased PDE8A expression after polyclonal activation | Increased PDE8A expression after polyclonal activation | PDE8A inhibition by enzymatic inhibitor or a PDE8A- Raf-1 kinase complex disruptor decreases Teff cell adhesion and migration under shear stress conditions | |
| CD4+ regulatory T(reg) cells | Low PDE8A (and all other PDEs expressed in T cells) | Low PDE8A (and all other PDEs expressed in T cells) | High cAMP levels in Treg cells | ; Vang et al., 2010; Vang et al., 2013; |
| T cells in systemic lupus erythematosus (SLE) | PDE8A1 | Upregulation of PDE8A1 transcripts in SLE T cells vs. normal controls | Orlowski et al., 2008 | |
| Macrophages | PDE8A | Promotes susceptibility to HIV-1 infection |
PDE8A expression and function in immune cells.
Additionally, very low levels of PDE1, PDE2, and PDE5 activity were also detected in CD4+ and CD8+ human T cells (Tenor et al., 1995).
Regulatory T(reg) Cells
As mentioned, PDE3 expression was found to be diminished in Treg cells as compared to CD4+ T cells (Gavin et al., 2007). Subsequently it was found that gene expression of Pde1B, Pde2A, Pde3B, Pde4B, Pde5A, Pde7A, and Pde8A and protein expression of PDE3B, PDE4B2, and PDE8Awere all reduced in Treg cells as compared to CD4+ Teff cells (, ; Vang et al., 2010, 2013; Vaeth et al., 2011; ). The low expression levels of PDEs in Treg cells and high level of cAMP have been linked to the mechanism by which Treg cells suppress the function of effector T(eff) cells through the direct cell-to-cell transfer of cAMP ().
PDE8A But Not PDE4 Is Controlling Activated T Cell Motility
Inhibition of PDEs regulates T cell proliferation, cytokine production and motility (Sommer et al., 1997; Pette et al., 1999; ; Vang et al., 2010, 2016; ; Mosenden and Tasken, 2011; Wehbi and Tasken, 2016; ; Figure 1). Only a small number of PDEs are currently targeted by approved therapeutics, and there is a significant knowledge gap about the specific and potentially therapeutic role of other PDE isoforms. This led to the development of novel PDE inhibitors, including those for therapy of inflammatory conditions. Recently, there have been numerous studies on PDE8A and PDE8B, a family of cAMP specific PDEs (Fisher et al., 1998a; Hayashi et al., 1998; Soderling et al., 1998a; Glavas et al., 2001; Kobayashi et al., 2003; Dong et al., 2006, 2010, 2015; Chen et al., 2009; Vang et al., 2010, 2016; DeNinno et al., 2011; Tsai and Beavo, 2012; Brown et al., 2013; Demirbas et al., 2013; Maurice, 2013; Shimizu-Albergine et al., 2016; ; Johnstone et al., 2017; Kelly, 2018). PDE8A and B are expressed widely in human tissue (Wang et al., 2008) with functions identified in testosterone and corticosteroid production (Tsai et al., 2010; Demirbas et al., 2013), myocyte contraction (Patrucco et al., 2010), lymphocyte adhesion and chemotaxis (Dong et al., 2006, 2015; Vang et al., 2010, 2013; ), memory and coordination (Tsai et al., 2012), human airway smooth muscle regulation (Johnstone et al., 2017), strong association with immune protection against intracellular pathogens (), brain disorders associated with inflammation (Chimienti et al., 2019) and T cells in systemic lupus erythematosus (SLE) (Orlowski et al., 2008). In a recent study, single nucleotide polymorphisms in the PDE8 region were found to be associated with Sjögren’s Syndrome (Taylor et al., 2017). T cell activation induces PDE8A1 (Glavas et al., 2001), a PDE isoform with a cAMP affinity up to 100 times higher than PDE4 isoforms (Fisher et al., 1998a; Hayashi et al., 1998; Soderling et al., 1998a; Gamanuma et al., 2003; ). This property of the PDE8 family suggests that they may regulate changes of baseline cAMP gradients around cell signaling complexes. The availability of PDE8 inhibitors and disruptors (Table 3) greatly enhanced the ability to conduct studies on the function of PDE8 in vitro and in vivo.
TABLE 3
| Inhibitor, selectivity | References |
| PF-4957325, PDE8A/B | Vang et al., 2010; DeNinno et al., 2011; DeNinno, 2012 |
| BC8–15, Dual PDE4/8 | Demirbas et al., 2013 |
| Dual PDE7/8 | Jankowska et al., 2017 |
| Multiple PDE8 inhibiting compounds | Vang et al., 2010; DeNinno et al., 2011; DeNinno, 2012 |
| Dipyridamole, PDE 4–8, 10, and 11 | Lerner and Epstein, 2006 |
| Multiple 2-chloroadenine derivatives, PDE8A | Huang et al., 2020 |
| Cell-penetrating peptide agent (PPL-008) inhibiting the PDE8A–C-Raf complex | |
| Stearylated cell-permeable peptide disrupting the Raf-1–PDE8A Complex based on the Raf-1–docking sequence from PDE8A, encompassing residues R454–T465 | Brown et al., 2013 |
Broad and selective PDE8 inhibitors.
It was shown that PDE8A regulates motility of lymphocytes and breast cancer cells, including adhesion to endothelial cells under physiological shear stress and chemotaxis (Dong et al., 2006, 2015; Vang et al., 2010, 2013; ). This seems to be a unique feature of PDE8 that is distinct from PDE4 activity (Vang et al., 2016). The therapeutic potency of biologics and compounds interacting with molecular targets on pathogenic T cells has been shown in vitro and in vivo (Yednock et al., 1992; Brocke et al., 1999; Steinman, 2005; Healy and Antel, 2016). Current observations demonstrate PDE8 to be one of those targets for blocking Teff cell motility and potentially inflammation (Dong et al., 2006, 2015; Vang et al., 2010, 2013, 2016; ). The potential role of PDE8 in models of inflammation and cancer is summarized in Table 4.
TABLE 4
| PDE8 isoform/assay | Model and Function | References |
| PDE8A/Expression study | Temporal changes of PDE8A expression in CD4+ T cell specific for a cytochrome C peptide/I-Ek antigen complex transferred into wildtype (non-transgenic) mice, activated with antigen in vivo. | Vang et al., 2010 |
| PDE8A/Expression study | CD4+ and CD4– T cell populations in a model of ovalbumin-induced allergic airway disease in mice | Vang et al., 2016 |
| PDE8 inhibition study ex vivo and in vitro | T cells responding to myelin oligodendrocyte glycoprotein (MOG)peptide MOG35–551 | Vang et al., 2016 |
| PDE8A1/PDE8A2 Expression study | In vivo MOG35–55 activated CD4+CD25– effector and CD4+CD25+ regulatory cells1 | |
| PDE8A and B/Regulating T cell adhesion through inhibitor and peptide disruptor study | In vivo MOG35–55 activated CD4+CD25– effector and CD4+CD25+ regulatory T cells1 | |
| PDE 4–8, 10, and 11/Use of broad PDE inhibitor dipyridamole in vivo treatment | Treatment of experimental autoimmune encephalomyelitis2 | Sloka et al., 2013 |
| PDE8A-C-Raf complex/PDE8A-C-Raf complex disruptor PPL-008 | Treatment of human malignant MM415 melanoma cell line in vitro and a MM415 melanoma xenograft mouse model in vivo with cell-penetrating PDE8A-C-Raf complex disruptor peptide agent (PPL-008) leads to reduced phospho-ERK signaling and growth inhibition | ; |
| PDE8A and B/Expression study | Human breast adenocarcinoma estrogen receptor-positive MCF-7 and T-47D cell lines Human breast adenocarcinoma estrogen receptor-negative MDA-MB-123 MB-231 and MDA-MB-435 cell lines | Dong et al., 2015 |
| PDE8A and B, Expression study | Human breast cancer patient biopsies and tissue arrays | Dong et al., 2015 |
| PDE8A and B, Inhibitor study | Inhibition of MDA-MB-231 breast cancer cell migration and wound healing | Dong et al., 2015 |
| PDE 4–8, 10, and 11/Use of the broad PDE inhibitor dipyridamole in vivo treatment | Prevention of triple-negative breast-cancer progression in a mouse model | Virgilio et al., 2012; Spano et al., 2013 |
| PDE 4–8, 10, and 11/Use of the broad PDE inhibitor dipyridamole in vivo treatment | Delay of breast cancer lesion onset, tumor progression and suppression of lung metastasis in a mouse model | Wang et al., 2013b |
PDE8 in models of inflammation and cancer.
1Myelin oligodendrocyte glycoprotein (MOG) peptide MOG35–55 is a myelin autoantigen used to induce experimental autoimmune encephalomyelitis (EAE) in vivo and is recognized by T and B cells in multiple sclerosis (MS). 2Experimental autoimmune encephalomyelitis (EAE) is an autoimmune disease model for multiple sclerosis (MS).
Differential Roles of PDEs in T Cell Adhesion
Previous studies on the role of PDE8 were done using the prototypic chemokine CXCL12 which is known to induce migration of leukocytes, including murine splenocytes (Cinamon et al., 2001). As measured in a transwell assay system CXCL12 stimulates equally the migration of mouse splenocytes, both unstimulated and stimulated with the mitogen concanavalin A (Con A). Interestingly, when probing the cAMP signaling pathway in CXCL12-induced chemotaxis, differential effects were observed on directed leukocyte migration between exposure of cells to a cell permeable cAMP analog vs. stimulation of adenylyl cyclase or inhibition of PDE. While CXCL12 dependent chemotaxis of both naïve and mitogen activated splenocytes was inhibited by direct exposure to dibutyryl cAMP, activated cells were resistant to indirect cAMP regulation through stimulation of adenylyl cyclase or PDE inhibition (Dong et al., 2006). Activation of adenylyl cyclase through Forskolin (Fsk) or PDE inhibition through the broad PDE enzymatic inhibitor IBMX, significantly reduced CXCL12-induced migration of naive but not activated splenocytes. Additionally, chemotaxis of mitogen-activated splenocytes was not inhibited by PDE3-, PDE4-, and PDE7-selective inhibitors. It is important to note that IBMX is a pan-cAMP specific PDE inhibitor that inhibits all known cAMP PDEs with the exception of PDE8 (Soderling et al., 1998a; Soderling and Beavo, 2000). In contrast, dipyridamole (DP), a broad PDE inhibitor that also targets PDE8 (Soderling et al., 1998a), was found to inhibit migration of naïve and activated splenocytes in response to CXCL12 (Dong et al., 2006). Addition of Fsk in combination with DP increased inhibition of chemotaxis of both naïve and activated splenocytes.
Of note, Rp-cAMPS, an inhibitor of PKA, reversed the DP mediated inhibition of splenocyte migration when exposed to CXCL12. DP is also known to inhibit nucleoside transporters, thereby increasing extracellular adenosine which causes increased levels of cAMP in T cells (Wang et al., 2013a). However, in these assays the action of DP on motility was unaffected by extracellular adenosine deaminase, suggesting that the effect of DP is independent of a possible increase in extracellular adenosine. Expression studies of splenocyte and T cell mRNA demonstrated upregulation of PDE4B2, PDE7A1 and A3, and PDE8A1 in response to T cell activation (Glavas et al., 2001; Dong et al., 2006; Vang et al., 2010). The results indicate that PDE8A1 may have a critical function in regulating cAMP pools that control T cell motility (Dong et al., 2006).
PDE8A Expression in Effector T (Teff) Cells in vivo
PDE8 expression was not only seen in unactivated and polyclonally stimulated splenocytes and CD4+ T cells in vitro, but also in highly purified CD4+ T cell populations in vivo. In a widely used TCR transgenic mouse model to investigate highly purified T cell populations in vivo in the absence of other leukocytes (, ), it was shown that antigenic activation resulted in PDE3, 4, and 8 expression in the transgenic T cell subset. Expression levels of the PDE8A gene in activated CD4+ T cells were up to fifty percent of those of the PDE3B and PDE4B genes (Vang et al., 2010).
Selective Inhibition of PDE8 Blocks Splenocyte Adhesion
Integrins including αL or α4 chains have been shown to promote firm adhesion to endothelial cell ligands. cAMP is known to regulate expression and activation of integrin molecules on lymphocytes and other leukocyte populations.
As mentioned, DP was found to inhibit PDE8 and leukocyte migration. Incubation with DP led to a significant reduction of the proportion of αLhi and α4hi Teff cells.
In contrast, IBMX did not significantly reduce integrin surface expression. Similarly, DP reduced the proportion of activated splenocytes to endothelial cells while IBMX did not have the same effect (Vang et al., 2010). Of note, the potent PDE4 inhibitor piclamilast (PICL) and the PDE3 inhibitor motapizone also did not suppress adhesion. Further, no significant effect of the canonical PDE4 inhibitor rolipram was reported when the interactions between activated T cells and immobilized VCAM-1 or endothelial cells were tested. The specific role of PDE8 action in T cell adhesion could be confirmed using PF-4957325, a selective PDE inhibitor with IC50 for PDE8A = 0.0007 μM and IC50 for PDE8B < 0.0003 μM, and with IC50 for all other PDEs > 1.5 μM (Vang et al., 2010; DeNinno et al., 2011; DeNinno, 2012; Tables 1, 3). As with DP, PF-4957325 significantly suppressed T cell blast adhesion to endothelial cells. Interestingly, when tested in T cell proliferation in response to anti-CD3 stimulation, PICL was significantly more potent at inhibiting T cell proliferation in comparison to PF-4957325 at identical concentrations. These data suggest a specific role for PDE8 in regulating Teff cell adhesion to endothelial cells. Subsequently, it was shown that cAMP signaling controls adhesion in these assays which could account for the effect of PDE8 inhibition.
One of the mechanisms by which cAMP regulates T cell adhesion is through the action of PKA which regulates cell surface expression and affinity of integrin molecules and phosphorylates α4 integrin involved in cellular adhesion (Goldfinger et al., 2003; Lim et al., 2007; Chilcoat et al., 2008). Thus, dibutyryl-cAMP, acting through PKA, inhibits T cell adhesion to endothelial cell ligands. The effect of increased cAMP levels on cell adhesion was not reversed by CXCL12 (Vang et al., 2010).
Endothelial Cells Also Express PDE8A
Cells of the murine brain endothelium-derived cell line bEnd.3, a polyoma virus middle T oncogene expressing endothelioma cell line (Montesano et al., 1990; Takeuchi and Baichwal, 1995) used for in vitro adhesion studies (Vang et al., 2010, 2016; ), have been shown to express PDE1, 2, 3, 4, 5, and 7 (; Netherton and Maurice, 2005). Additionally, bEnd.3 cells express PDE8A at levels that are about 25 percent of PDE4B, which is comparable to expression of PDE2A, a functionally critical isoform in endothelial cells (Vang et al., 2010). DP did not induce PDE8A in bEnd.3 or T cells. These results are in contrast to PDE4B which was significantly upregulated in both of these cell populations in response to the increase in intracellular cAMP. These differential responses of PDEs to cAMP signaling further point to different and non-overlapping roles of PDE8 and other PDE isoforms within the same cell populations (Vang et al., 2010).
PDE8A Gene Expression in CD4+ CD25+ Regulatory T (Treg) Cells
It is well established that Teff cells and Treg cells express significantly different levels of PDEs. The transcription factor forkhead box P3 (Foxp3) expressed in Treg cells has been shown to selectively repress genes, including PDE genes, leading to elevated levels of intracellular cAMP (, ; Vaeth et al., 2011).
Remarkably, the Treg cell subsets show significantly lower expression for Pde1a, Pde1b, Pde2a, Pde 3b, Pde 4b, Pde5a, Pde7a, and Pde8a genes compared to naive Teff cell subsets. In addition to lower expression of PDE3B and PDE4B2, T reg cells express significantly lower levels of PDE8A in comparison to Teff cells (Vang et al., 2013). Consistent with these findings, it was shown that Foxp3 represses PDE3B, while reduced PDE3B expression through genetic means permits normal Treg cell homeostasis and Treg cell-specific gene expression (Gavin et al., 2007). In contrast, Treg and Teff cells express comparable levels of PDE4B3, PDE4D, and PDE7A (Vang et al., 2013). While the regulation of select PDE isoforms including PDE8 through Foxp3 in Treg cells is well established, the exact role of PDE isoforms regulating Treg cell function remains to be elucidated.
CD4+ T Cells Selectively Express PDE8A in Inflammatory Disease
PDE8A but not PDE8B has been shown to be expressed in T cells (Hayashi et al., 1998, 2002; Dong et al., 2006, 2010).
To test the potential of PDE8 as a target to treat inflammation in vivo, the expression of PDE8 was determined in draining lymph nodes of mice that were immunized with ovalbumin (OVA) in an allergic airway disease (AAD) model (Vang et al., 2016).
In this mouse model of AAD, clinical and pathologic resolution occurs with long-term exposure to OVA aerosol. T cells accumulate in hilar and inguinal lymph nodes that drain the exposed lung tissue. The expression of PDE8A protein was determined by Western immunoblot in the CD4+ T cell population that was isolated from the lymph nodes at various time points after the induction of AAD. It was found that PDE8A was significantly higher in the CD4+ population as compared to the CD4– lymph node populations. Importantly, the increased PDE8A expression was only seen in in vivo activated CD4+ T cell populations, i.e., after antigen exposure, but not in CD4+ T cells from naïve lymph nodes.
Taken together, these results demonstrate that PDE8A expression is higher in the hilar CD4+ lymph node cell population than in the hilar CD4– lymph node cell population at various stages of AAD. Additionally, expression levels of the Pde8a gene were higher during the acute AAD phase than at the late stage tolerance stage of the disease model (Vang et al., 2016).
PDE8 and PDE4 Inhibition Show Differential Effects on the in vitro Adhesion of T Cells to Endothelial Cells
Studies including a combination of selective and broad PDE inhibitors established overlapping and distinct effects of PDEs in T cell adhesion. Specifically, only the use of PDE inhibitors that target PDE8, including the broad PDE8 inhibitor DP and the highly PDE8-selective inhibitor PF-04957325 (Vang et al., 2010), demonstrated significant inhibition of splenocyte and T cell adhesion. Of note, the PDE inhibitor IBMX, which inhibits all known PDEs that hydrolyze cAMP with the exception of PDE8, shows little inhibitory effect when tested in assays measuring T cell adhesion to endothelial cells. Surprisingly, the potent PDE4 inhibitor PICL showed opposite effects both when used alone or in combination with a PDE8 inhibitor by enhancing adhesion of T cells to endothelial cells. Taken together, these studies show that PDE4 and PDE8 inhibitors exert opposite effects on T cell–endothelial cell interactions in adhesion assays (Vang et al., 2016).
Opposing Effects of PDE8 and PDE4 Inhibitors on Proliferation of Antigen or Anti-CD3 Stimulated T Cells
In contrast to the observations in adhesion assays, T cell proliferation could be significantly inhibited by the PDE4 inhibitor PICL while the PDE8 inhibitor PF-04957325 showed little effect on proliferation in these studies (Vang et al., 2016). This indicates an action of PDE8 inhibitors on T cell adhesion that is independent of the well-documented inhibition of mitogen-activated protein kinase (MAP) kinase signaling by PDE inhibitors (Giembycz et al., 1996; Essayan et al., 1997; ). T cells that were stimulated by specific antigen or anti-CD3 in vitro responded significantly lower in proliferation assays when exposed to PICL in comparison to exposure of equal doses of PF-04957325. Importantly, the opposing effects that were seen in adhesion assays were not seen in proliferation assays since combining PICL and PF-04957325 led to a small increase in suppression of proliferation (Vang et al., 2016). These results clearly demonstrate differential actions of PDE4 and PDE8 in regulating key T cell functions.
Regulation of Vascular Adhesion of Teff Cells vs. Treg Cells Through Inhibition of PDE8 Under Physiologic Shear Stress
It was found that Treg cells form significantly stronger tethers to endothelial cells compared to Teff cells (Maganto-Garcia et al., 2011). It was also established that PDE8A expression in Teff cells differed significantly from that in Treg cells (Vang et al., 2013). Based on these observations adhesion and migration of Teff and Treg cells were investigated for the effects of PDE8 inhibition on these processes (). This question was addressed in a mouse model of autoimmune disease using encephalitogenic Teff cell populations mediating experimental autoimmune encephalomyelitis (EAE). T cells were isolated from draining lymph nodes of mice immunized with a myelin derived peptide, myelin oligodendrocyte glycoprotein (MOG)35–55, an antigen that is used to induce EAE in susceptible strains of mice (Brocke et al., 1996; ). PDE8A1 and PDE8A2 expression at the protein level was compared in the fraction of CD4+CD25– Teff cells and CD4+CD25+ Treg cells, and it was shown that there was significantly higher expression of these PDE8 isoforms in Teff cells than in Treg cells (Vang et al., 2013). However, expression of rapidly accelerated fibrosarcoma (Raf)-1 in Teff cells was not significantly different from that in Treg cells ().
Previous studies demonstrated that Raf-1 profoundly regulates cell motility (Juliano et al., 2004). A study addressing the role of PDE8 in this process used T cells that were derived from Foxp3gfp.KI mice (). In these mice, expression of FoxP3, a known regulator of the development of functional Treg cell populations, is tagged with green fluorescent protein (GFP). Using Teff and Treg cell populations from these mice immunized with the myelin derived peptide facilitated separate measurements of inhibitor effects on each cell population under identical conditions. A flow chamber model using physiologic shear stress to measure various categories of tethers of T cell populations to bEnd.3 cells was employed. PDE8 inhibition using PF-04957325 significantly reduced firm tethers of CD4+Foxp+GFP– Teff cells. In contrast, no significant effect of PDE8 inhibition was observed in adhesion assays of CD4+Foxp+GFP+ Treg cells. It is conceivable that the different sensitivity of Teff and Treg cells to PDE8 inhibition when forming firm adhesive tethers is related to the different expression levels of PDE8A in both cell populations ().
Adhesion of Teff Cells to Endothelial Cells Is Regulated by a PDE8A-Raf-1 Kinase Signaling Complex
The studies on PDE8 inhibition were followed by mechanistic investigations testing the role of the signaling complex formed by PDE8A and Raf-1 kinase in regulating adhesion of Teff and Treg cells to endothelial cells (). Both molecules assemble in the cytoplasm whereby PDE8A protects RAF-1 kinase from PKA mediated inhibitory phosphorylation (Brown et al., 2013; Maurice, 2013). Vascular adhesion of T cells has been shown to be regulated by members of the Ras family of signaling molecules (Brown et al., 2014). Disruption of the PDE8A-Raf-1 complex by a cell permeable peptide specifically engineered to disrupt this complex (Brown et al., 2013) was tested for its effect on CD4+ T cell adhesion and migration under shear stress conditions. Adhesion of CD4+GFP–Foxp3– Teff cells to vascular endothelial cells was significantly decreased by the disruptor peptide in experiments employing CD4+ T cells isolated from the draining lymph nodes of Foxp3gfp.KI mice immunized with MOG35–55, whereas a scrambled control peptide was without effect. Disruption of the PDE8A-Raf-1 complex by the peptide similarly decreased adhesion, spreading and locomotion of Teff cells to isolated ICAM-1 molecules. In contrast, the use of PF-04957325 which targets the enzymatic site of PDE8, did not show comparable effects (). In further comparing the disruptor peptide with the PDE8 enzymatic inhibitor, PF-04957325, it was found that adhesion of CD4+ Teff or Treg cells via LFA-1 integrin to ICAM-1 was not markedly altered through the exposure to PF-04957325. In contrast the PDE8A-Raf-1 disruptor peptide significantly reduced cell adherence, spreading and locomotion of CD4+GFP–Foxp3– Teff cells. The disruptor peptide also reduced transient Treg cell adhesion to ICAM-1, while having no effect on firm tether formation and detachment of these cells. Taken together, this indicates the tether formation between LFA-1 and ICAM-1 on T cells and vascular targets is in part regulated by a signaling complex that is formed between PDE8A and Raf-1. The regulation appears to be LFA-1 integrin specific in that no significant effects were observed when the VLA-4–VCAM-1 interactions were examined using the comparable assay systems and cells ().
Inhibition of PDE8 Catalytic Activity Significantly Suppresses Extracellular Signal-Regulated Kinase (ERK) Phosphorylation in Activated CD4+ T Cells
Inhibition of PDE8 catalytic activity and disruption of the complex of PDE8A-Raf-1 were both investigated for their potential to affect Raf-1 or ERK signaling by analyzing Raf-1 phosphorylation at residue S259 that inhibits its activity (Brown et al., 2013; Maurice, 2013) by PKA and the phosphorylation sites known to activate ERK1/2 in CD4+ T cells that were treated with PF-04957325 or disruptor peptide and polyclonally activated (). Inhibitory Raf-1 phosphorylation at S259 and activating ERK1/2 phosphorylation at residues Thr202/Tyr204 were determined by Western immunoblot. Inhibitor treatment did not affect phosphorylation of Raf-1, but a significant decrease of the phosphorylation of ERK1/2 was seen after inhibitor treatment of Teff cells. These observations demonstrate an effect of PDE8 on the ERK1/2 signaling pathway as has been seen with PDE4 in T cells (). Of note, the abundance of PDE8A increased in response to PDE8 inhibition. Similar results were reported for PDE7A, PDE3B, PDE4B, and PDE4D which were increased when cAMP was elevated in cells (Jiang et al., 1998; Lee et al., 2002; Moon et al., 2002), and this upregulation apparently occurs with PDE8A as well.
PDE8A-Raf-1 Complex Disruption Within Activated Teff Cells Leads to Raf-1 and ERK1/2 Phosphorylation With Opposing Effects
Treatment of CD4+ T cells with the complex disruptor peptide increases phosphorylation of Raf-1 at the inhibitory site at S259 while phosphorylation of ERK1/2 increases at activating sites at Thr202/Tyr204 (). Based on these observations, it is conceivable that the PDE8A-Raf-1 complex regulates motility of T cells through Raf-1 and not through the canonical ERK-MAPK pathway. The exact mechanism underlying these experimental results needs to be elucidated since the reported increase in the phosphorylation of ERK within activated Teff cells can be the result of actions of many effectors interacting in this process (Kortum et al., 2013).
PDE8A and Breast Cancer Cell Motility
It has been observed that stimulation of cAMP signaling, in many cases through inhibition of PDEs, inhibits migration and motility of some types of cells, including fibroblasts (Fleming et al., 2004), epithelial cells (Lyle et al., 2008), endothelial cells (Netherton and Maurice, 2005), melanoma cells (Dua and Gude, 2008), colon cancer cells (Murata et al., 2000), pancreatic cancer cells (Burdyga et al., 2013; Zimmerman et al., 2015), bladder cancer cells (Ou et al., 2014), cervical cancer cells (Lee et al., 2014), and breast cancer cells (Dong et al., 2015). In the breast cancer study a complete analysis of the expression of PDE genes at the mRNA and protein level in established estrogen receptor positive and negative breast cancer cell lines and in patients’ primary breast cancer biopsies by microarray analysis, qPCR, Western blot analysis, immunofluorescence and immunohistochemistry was performed (Dong et al., 2015). Although a wide range of PDE genes were seen to be expressed in some of these breast cancers by these methods, the PDE8A gene was prominently expressed at the mRNA level in all the breast cancer cells as well as all the breast cancer tissues examined. In addition to its prominent expression in breast cancer cells, expression of PDE8A in the form of an AKAP13-PDE8A fusion transcript has been reported to be highly recurrent in colon cancer cells as well (Nome et al., 2013). Breast cancer cell migration was analyzed both by transwell migration and wound healing assays, and was found to be inhibited by several agonistic cAMP analogs, Fsk, and several PDE inhibitors, in particular DP and the PDE8 selective inhibitor, PF-04957325. Therefore, consistent with our observation of PDE8A being important in the regulation of lymphocyte chemotaxis, it may also be an important regulator, and thus an important target for control of breast cancer cell migration as well.
Conclusion
Numerous studies demonstrate that T cell adhesion and migration under shear stress conditions are regulated by the enzymatic activity of PDE8 proteins. Additionally, the PDE8A-Raf-1 kinase signaling complex has been identified as a functional site for PDE8A controlling T cell motility (Figure 1). Inasmuch as treatment with the peptide designed to disrupt the PDE8A-Raf-1 complex led to phosphorylation of Raf-1 at an inhibitory site but phosphorylation of ERK1/2 at activating sites, it suggests that PDE8 displacement from the complex exerts a Raf-1 dependent but ERK independent effect on T cell motility. Thus, it is conceivable that the effect of PDE8 inhibition on the formation of tethers and directed migration by T cells is mediated by Raf-1 but not ERK. This model is supported by reports demonstrating regulation of cell motility by Raf-1 and B-Raf through Rho GTPases regulating the actin cytoskeleton and focal adhesions (Ehrenreiter et al., 2005; Klein et al., 2008). The studies on PDE8 identify a novel signaling complex of PDE8-RAF regulating CD4+ T cell motility. Upon T cell activation through the TCR, Raf-1 links Ras activation to MAPK signaling (Kortum et al., 2013). Of note, B-Raf most strongly interacts with Ras (Marais et al., 1997; Weber et al., 2000) and activates ERK (Pritchard et al., 1995, 2004; Wojnowski et al., 2000) while cell proliferation and ERK activation are independent of Raf-1. In contrast, Raf-1 is capable of activating Rho and inducing subsequent downstream events in migrating cells without MAPK activity (Ehrenreiter et al., 2005). Thus, MAPKs have been known to act independently in specific signaling pathways. Activation of ERK independent of Ras/Raf-1 can also occur through activation of T cells through the TCR (Kortum et al., 2013). An effect on T cell function that is independent of ERK is also suggested by the finding that PDE8 inhibition does not affect T cell proliferation (Vang et al., 2010, 2016). PDE4 inhibition has been shown to suppress T cell proliferation and ERK1 signaling (Norambuena et al., 2009), but T cell motility is little affected (Lerner and Epstein, 2006; Vang et al., 2016). Collectively, reports over the last few years suggest that PDE8 and the PDE8A-Raf-1 signaling complex selectively regulate the motility of T cells but not T cell proliferation and support the notion that PDE8A exerts its action primarily on Raf-1 kinase and not on MAPK signaling.
Statements
Author contributions
All authors researched the literature, wrote the manuscript, and reviewed and approved the final version. SB prepared the figure. CB and PE reviewed and approved the final figure.
Funding
We received support from the NMSS (grant no. RG 4544A1/1) on the Role of PDE8 in EAE, from the Smart Family Foundation on Targeting PDE8 for Treatment of Autoimmune Diseases and the Lea’s Foundation for Leukemia Research Inc. on phosphodiesterase as a Target for Leukemia Treatment. The funders had no influence on the research design and experiments.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbrahamsenH.BaillieG.NgaiJ.VangT.NikaK.RuppeltA.et al (2004). TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling.J. Immunol.1734847–4858. 10.4049/jimmunol.173.8.4847
2
AhmadF.MurataT.ShimizuK.DegermanE.MauriceD.ManganielloV. (2015). Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.Oral Dis.21e25–e50.
3
AkamaT.BakerS. J.ZhangY. K.HernandezV.ZhouH.SandersV.et al (2009). Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.Bioorg. Med. Chem. Lett.192129–2132. 10.1016/j.bmcl.2009.03.007
4
AmarandiR. M.HjortoG. M.RosenkildeM. M.KarlshojS. (2016). Probing biased signaling in chemokine receptors.Methods Enzymol.570155–186. 10.1016/bs.mie.2015.09.001
5
ArpJ.KirchhofM. G.BarojaM. L.NazarianS. H.ChauT. A.StrathdeeC. A.et al (2003). Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation.Mol. Cell. Biol.238042–8057. 10.1128/mcb.23.22.8042-8057.2003
6
AshikagaT.StradaS. J.ThompsonW. J. (1997). Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.Biochem. Pharmacol.541071–1079. 10.1016/s0006-2952(97)00287-6
7
AsirvathamA. L.GalliganS. G.SchillaceR. V.DaveyM. P.VastaV.BeavoJ. A.et al (2004). A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines.J. Immunol.1734806–4814. 10.4049/jimmunol.173.8.4806
8
BaillieG. S. (2009). Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases.FEBS J.2761790–1799. 10.1111/j.1742-4658.2009.06926.x
9
BaillieG. S.HouslayM. D. (2005). Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes.Curr. Opin. Cell Biol.17129–134. 10.1016/j.ceb.2005.01.003
10
BaillieG. S.TejedaG. S.KellyM. P. (2019). Therapeutic targeting of 3’,5’-cyclic nucleotide phosphodiesterases: inhibition and beyond.Nat. Rev. Drug Discov.18770–796. 10.1038/s41573-019-0033-4
11
BarnetteM. S.ChristensenS. B.EssayanD. M.GrousM.PrabhakarU.RushJ. A.et al (1998). SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.J. Pharmacol. Exp. Ther.284420–426.
12
BasoleC. P.NguyenR. K.LamotheK.VangA.ClarkR.BaillieG. S.et al (2017). PDE8 controls CD4(+) T cell motility through the PDE8A-Raf-1 kinase signaling complex.Cell Signal.4062–72. 10.1016/j.cellsig.2017.08.007
13
BeavoJ.HouslayM.FrancisS. (2007). “Cyclic nucleotide phosphodiesterase superfamily,” in Cyclic Nucleotide Phosphodiesterases in Health and Disease, edsBeavoJ. A.FrancisS. H.HouslayM. D. (New York, NY: CRC Press), 3–18. 10.1201/9781420020847-1
14
BenderA. T.BeavoJ. A. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.Pharmacol. Rev.58488–520. 10.1124/pr.58.3.5
15
Ben-SassonS. Z.Hu-LiJ.QuielJ.CauchetauxS.RatnerM.ShapiraI.et al (2009). IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.Proc. Natl. Acad. Sci. U.S.A.1067119–7124. 10.1073/pnas.0902745106
16
Ben-SassonS. Z.WangK.CohenJ.PaulW. E. (2013). IL-1beta strikingly enhances antigen-driven CD4 and CD8 T-cell responses.Cold Spring Harb. Symp. Quant. Biol.78117–124. 10.1101/sqb.2013.78.021246
17
BielekovaB.LincolnA.McfarlandH.MartinR. (2000). Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases.J. Immunol.1641117–1124. 10.4049/jimmunol.164.2.1117
18
BischoffE. (2004). Potency, selectivity, and consequences of nonselectivity of PDE inhibition.Int. J. Impot. Res.16(Suppl. 1) S11–S14.
19
BitonA.AnsorgeS.BankU.TagerM.ReinholdD.BrockeS. (2011). Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions.Immunobiology2161295–1301. 10.1016/j.imbio.2011.07.001
20
BjorgoE.MoltuK.TaskenK. (2011). Phosphodiesterases as targets for modulating T-cell responses.Handb. Exp. Pharmacol.204345–363. 10.1007/978-3-642-17969-3_15
21
BjorgoE.SolheimS. A.AbrahamsenH.BaillieG. S.BrownK. M.BergeT.et al (2010). Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex.Mol. Cell. Biol.301660–1672. 10.1128/mcb.00696-09
22
BjorgoE.TaskenK. (2006). Role of cAMP phosphodiesterase 4 in regulation of T-cell function.Crit. Rev. Immunol.26443–451. 10.1615/critrevimmunol.v26.i5.40
23
BlairC. M.BaillieG. S. (2019). Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes.Biochem. Soc. Trans.471405–1414. 10.1042/bst20190252
24
BlairC. M.WalshN. M.LittmanB. H.MarcouxF. W.BaillieG. S. (2019). Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.BMC Cancer19:266.
25
BlancoF. C.SoriaM. A.KleppL. I.BigiF. (2017). ERAP1 and PDE8A are downregulated in cattle protected against bovine tuberculosis.J. Mol. Microbiol. Biotechnol.27237–245. 10.1159/000479183
26
BloklandA.HeckmanP.VanmierloT.SchreiberR.PaesD.PrickaertsJ. (2019). Phosphodiesterase type 4 inhibition in CNS diseases.Trends Pharmacol. Sci.40971–985. 10.1016/j.tips.2019.10.006
27
BloomT. J.BeavoJ. A. (1996). Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants.Proc. Natl. Acad. Sci. U.S.A.9314188–14192. 10.1073/pnas.93.24.14188
28
BooimanT.Cobos JimenezV.Van DortK. A.Van ’T WoutA. B.KootstraN. A. (2014). Phosphodiesterase 8a supports HIV-1 replication in macrophages at the level of reverse transcription.PLoS One9:e109673. 10.1371/journal.pone.0109673
29
BoppT.BeckerC.KleinM.Klein-HesslingS.PalmetshoferA.SerflingE.et al (2007). Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression.J. Exp. Med.2041303–1310. 10.1084/jem.20062129
30
BoppT.DehzadN.ReuterS.KleinM.UllrichN.StassenM.et al (2009). Inhibition of cAMP degradation improves regulatory T cell-mediated suppression.J. Immunol.1824017–4024. 10.4049/jimmunol.0803310
31
BourneH. R.LichtensteinL. M.MelmonK. L.HenneyC. S.WeinsteinY.ShearerG. M. (1974). Modulation of inflammation and immunity by cyclic AMP.Science18419–28. 10.1126/science.184.4132.19
32
BrockeS.PiercyC.SteinmanL.WeissmanI. L.VeromaaT. (1999). Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment.Proc. Natl. Acad. Sci. U.S.A.966896–6901. 10.1073/pnas.96.12.6896
33
BrockeS.QuigleyL.McfarlandH. F.SteinmanL. (1996). Isolation and characterization of autoreactive T cells in experimental autoimmune encephalomyelitis of the mouse.Methods9458–462. 10.1006/meth.1996.0053
34
BrownK. M.DayJ. P.HustonE.ZimmermannB.HampelK.ChristianF.et al (2013). Phosphodiesterase-8A binds to and regulates Raf-1 kinase.Proc. Natl. Acad. Sci. U.S.A.110E1533–E1542.
35
BrownW. S.KhaliliJ. S.Rodriguez-CruzT. G.LizeeG.McintyreB. W. (2014). B-Raf regulation of integrin alpha4beta1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells.J. Biol. Chem.28923141–23153. 10.1074/jbc.m114.562918
36
BurdygaA.ConantA.HaynesL.ZhangJ.JalinkK.SuttonR.et al (2013). cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: effects of PKA and EPAC.Biochim. Biophys. Acta18332664–2672. 10.1016/j.bbamcr.2013.06.011
37
CallenderV. D.AlexisA. F.Stein GoldL. F.LebwohlM. G.PallerA. S.DesaiS. R.et al (2019). Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups.Am. J. Clin. Dermatol.20711–723. 10.1007/s40257-019-00450-w
38
ChenC.WickenheisserJ.EwensK. G.AnkenerW.LegroR. S.DunaifA.et al (2009). PDE8A genetic variation, polycystic ovary syndrome and androgen levels in women.Mol. Hum. Reprod.15459–469. 10.1093/molehr/gap035
39
ChilcoatC. D.ShariefY.JonesS. L. (2008). Tonic protein kinase A activity maintains inactive beta2 integrins in unstimulated neutrophils by reducing myosin light-chain phosphorylation: role of myosin light-chain kinase and Rho kinase.J. Leukoc Biol.83964–971. 10.1189/jlb.0405192
40
ChimientiF.CavarecL.VincentL.SalvetatN.ArangoV.UnderwoodM. D.et al (2019). Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents.Transl. Psychiatry9:91.
41
CinamonG.GrabovskyV.WinterE.FranitzaS.FeigelsonS.ShamriR.et al (2001). Novel chemokine functions in lymphocyte migration through vascular endothelium under shear flow.J. Leukoc Biol.69860–866.
42
ClaveauD.ChenS. L.O’keefeS.ZallerD. M.StyhlerA.LiuS.et al (2004). Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxy propan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.J. Pharmacol. Exp. Ther.310752–760. 10.1124/jpet.103.064691
43
ContiM.NemozG.SetteC.ViciniE. (1995). Recent progress in understanding the hormonal regulation of phosphodiesterases.Endocr. Rev.16370–389. 10.1210/edrv-16-3-370
44
ContiM.SwinnenJ. V. (1990). “Structure and function of the rolipram-sensitive low-Km cyclic AMP phosphodiesterases: a family of highly related enzymes,” in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edsBeavoJ.HouslayM. D. (West Sussex: John Wiley & Sons Ltd.), 243–265.
45
De SouzaA.StroberB. E.MerolaJ. F.OliverS.FranksA. G.Jr. (2012). Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.J. Drugs Dermatol.111224–1226.
46
DemirbasD.WymanA. R.Shimizu-AlbergineM.CakiciO.BeavoJ. A.HoffmanC. S. (2013). A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition.PLoS One8:e71279. 10.1371/journal.pone.0071279
47
DeNinnoM. P. (2012). Future directions in phosphodiesterase drug discovery.Bioorg. Med. Chem. Lett.226794–6800. 10.1016/j.bmcl.2012.09.028
48
DeNinnoM. P.WrightS. W.VisserM. S.EtienneJ. B.MooreD. E.OlsonT. V.et al (2011). 1,5-Substituted nipecotic amides: selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability.Bioorg. Med. Chem. Lett.213095–3098. 10.1016/j.bmcl.2011.03.022
49
DongC.VirtucioC.ZemskaO.BaltazarG.ZhouY.BaiaD.et al (2016). Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes.J. Pharmacol. Exp. Ther.358413–422. 10.1124/jpet.116.232819
50
DongH.ClaffeyK. P.BrockeS.EpsteinP. M. (2015). Inhibition of breast cancer cell migration by activation of cAMP signaling.Breast Cancer Res. Treat.15217–28. 10.1007/s10549-015-3445-9
51
DongH.OsmanovaV.EpsteinP. M.BrockeS. (2006). Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes.Biochem. Biophys. Res. Commun.345713–719. 10.1016/j.bbrc.2006.04.143
52
DongH.ZittC.AurigaC.HatzelmannA.EpsteinP. M. (2010). Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells.Biochem. Pharmacol.79321–329. 10.1016/j.bcp.2009.09.001
53
DuaP.GudeR. P. (2008). Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation.Eur. J. Cancer441587–1595. 10.1016/j.ejca.2008.04.009
54
EhrenreiterK.PiazzollaD.VelamoorV.SobczakI.SmallJ. V.TakedaJ.et al (2005). Raf-1 regulates Rho signaling and cell migration.J. Cell. Biol.168955–964. 10.1083/jcb.200409162
55
EkholmD.HemmerB.GaoG.VergelliM.MartinR.ManganielloV. (1997). Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.J. Immunol.1591520–1529.
56
EpsteinP. M.HachisuR. (1984). Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts.Adv. Cyclic Nucleotide Protein Phosphorylation Res.16303–324.
57
EpsteinP. M.MillsJ. S.HershE. M.StradaS. J.ThompsonW. J. (1980). Activation of cyclic nucleotide phosphodiesterase from isolated human peripheral blood lymphocytes by mitogenic agents.Cancer Res.40379–386.
58
EpsteinP. M.MoraskiS.Jr.HachisuR. (1987). Identification and characterization of a Ca2+-calmodulin-sensitive cyclic nucleotide phosphodiesterase in a human lymphoblastoid cell line.Biochem. J.243533–539. 10.1042/bj2430533
59
EpsteinP. M.StradaS. J.SaradaK.ThompsonW. J. (1982). Catalytic and kinetic properties of purified high-affinity cyclic AMP phosphodiesterase from dog kidney.Arch. Biochem. Biophys.218119–133. 10.1016/0003-9861(82)90327-7
60
ErdoganS.HouslayM. D. (1997). Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.Biochem. J.321(Pt 1)165–175. 10.1042/bj3210165
61
EssayanD. M.HuangS. K.Kagey-SobotkaA.LichtensteinL. M. (1997). Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression.J. Allergy Clin. Immunol.9928–37. 10.1016/s0091-6749(97)81041-x
62
FawcettL.BaxendaleR.StaceyP.McgroutherC.HarrowI.SoderlingS.et al (2000). Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.Proc. Natl. Acad. Sci. U.S.A.973702–3707. 10.1073/pnas.97.7.3702
63
FisherD. A.SmithJ. F.PillarJ. S.St DenisS. H.ChengJ. B. (1998a). Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase.Biochem. Biophys. Res. Commun.246570–577. 10.1006/bbrc.1998.8684
64
FisherD. A.SmithJ. F.PillarJ. S.St DenisS. H.ChengJ. B. (1998b). Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase.J. Biol. Chem.27315559–15564. 10.1074/jbc.273.25.15559
65
FlemingY. M.FrameM. C.HouslayM. D. (2004). PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration.J. Cell Sci.1172377–2388. 10.1242/jcs.01096
66
FrancisS. H.HouslayM. D.ContiM. (2011). Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action.Handb. Exp. Pharmacol.20447–84. 10.1007/978-3-642-17969-3_2
67
FrancisS. H.ThomasM. K.CorbinJ. D. (1990). “Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from lung,” in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edsBeavoJ.HouslayM. D. (West Sussex: John Wiley & Sons Ltd.), 117–139.
68
FujishigeK.KoteraJ.MichibataH.YuasaK.TakebayashiS.OkumuraK.et al (1999a). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A).J. Biol. Chem.27418438–18445. 10.1074/jbc.274.26.18438
69
FujishigeK.KoteraJ.OmoriK. (1999b). Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A.Eur. J. Biochem.2661118–1127. 10.1046/j.1432-1327.1999.00963.x
70
GamanumaM.YuasaK.SasakiT.SakuraiN.KoteraJ.OmoriK. (2003). Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans.Cell Signal.15565–574. 10.1016/s0898-6568(02)00146-8
71
GantnerF.GotzC.GekelerV.SchudtC.WendelA.HatzelmannA. (1998). Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.Br. J. Pharmacol.1231031–1038. 10.1038/sj.bjp.0701688
72
GantnerF.KustersS.WendelA.HatzelmannA.SchudtC.TiegsG. (1997a). Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors.J. Pharmacol. Exp. Ther.28053–60.
73
GantnerF.TenorH.GekelerV.SchudtC.WendelA.HatzelmannA. (1997b). Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study.J. Allergy Clin. Immunol.100527–535. 10.1016/s0091-6749(97)70146-5
74
GardnerC.RobasN.CawkillD.FidockM. (2000). Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase.Biochem. Biophys. Res. Commun.272186–192. 10.1006/bbrc.2000.2743
75
GavinM. A.RasmussenJ. P.FontenotJ. D.VastaV.ManganielloV. C.BeavoJ. A.et al (2007). Foxp3-dependent programme of regulatory T-cell differentiation.Nature445771–775. 10.1038/nature05543
76
GiembyczM. A. (2000). Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?Drugs59193–212. 10.2165/00003495-200059020-00004
77
GiembyczM. A.CorriganC. J.SeyboldJ.NewtonR.BarnesP. J. (1996). Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2.Br. J. Pharmacol.1181945–1958. 10.1111/j.1476-5381.1996.tb15629.x
78
GillespieP. G. (1990). “Phosphodiesterases in visual transduction by rods and cones,” in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edsBeavoJ.HouslayM. D. (West Sussex: John Wiley & Sons Ltd.), 163–183.
79
GillespieP. G.BeavoJ. A. (1989). Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948.Mol. Pharmacol.36773–781.
80
GlavasN. A.OstensonC.SchaeferJ. B.VastaV.BeavoJ. A. (2001). T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3.Proc. Natl. Acad. Sci. U.S.A.986319–6324. 10.1073/pnas.101131098
81
GoldfingerL. E.HanJ.KiossesW. B.HoweA. K.GinsbergM. H. (2003). Spatial restriction of alpha4 integrin phosphorylation regulates lamellipodial stability and alpha4beta1-dependent cell migration.J. Cell Biol.162731–741. 10.1083/jcb.200304031
82
Gonzalez-GarciaC.BravoB.BallesterA.Gomez-PerezR.EguiluzC.RedondoM.et al (2013). Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.Br. J. Pharmacol.170602–613. 10.1111/bph.12308
83
GorayaT. A.CooperD. M. (2005). Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives.Cell Signal.17789–797. 10.1016/j.cellsig.2004.12.017
84
GotoM.MurakawaM.Kadoshima-YamaokaK.TanakaY.InoueH.MurafujiH.et al (2009). Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and cytokine production of NKT cells.Cell Immunol.258147–151. 10.1016/j.cellimm.2009.04.005
85
GuoJ.WatsonA.KempsonJ.CarlsenM.BarbosaJ.StebbinsK.et al (2009). Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.Bioorg. Med. Chem. Lett.191935–1938. 10.1016/j.bmcl.2009.02.060
86
HanP.ZhuX.MichaeliT. (1997). Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart.J. Biol. Chem.27216152–16157. 10.1074/jbc.272.26.16152
87
HatzelmannA.MorcilloE. J.LungarellaG.AdnotS.SanjarS.BeumeR.et al (2010). The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.Pulm. Pharmacol. Ther.23235–256. 10.1016/j.pupt.2010.03.011
88
HatzelmannA.SchudtC. (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.J. Pharmacol. Exp. Ther.297267–279.
89
HayashiM.MatsushimaK.OhashiH.TsunodaH.MuraseS.KawaradaY.et al (1998). Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase.Biochem. Biophys. Res. Commun.250751–756. 10.1006/bbrc.1998.9379
90
HayashiM.ShimadaY.NishimuraY.HamaT.TanakaT. (2002). Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene.Biochem. Biophys. Res. Commun.2971253–1258. 10.1016/s0006-291x(02)02371-9
91
HealyL. M.AntelJ. P. (2016). Sphingosine-1-phosphate receptors in the central nervous and immune systems.Curr. Drug Targets171841–1850. 10.2174/1389450116666151001112710
92
HetmanJ. M.RobasN.BaxendaleR.FidockM.PhillipsS. C.SoderlingS. H.et al (2000a). Cloning and characterization of two splice variants of human phosphodiesterase 11A.Proc. Natl. Acad. Sci. U.S.A.9712891–12895. 10.1073/pnas.200355397
93
HetmanJ. M.SoderlingS. H.GlavasN. A.BeavoJ. A. (2000b). Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase.Proc. Natl. Acad. Sci. U.S.A.97472–476. 10.1073/pnas.97.1.472
94
HouslayM. D.SullivanM.BolgerG. B. (1998). The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions.Adv. Pharmacol.44225–342. 10.1016/s1054-3589(08)60128-3
95
HuangY.WuX. N.ZhouQ.WuY.ZhengD.LiZ.et al (2020). Rational design of 2-chloroadenine derivatives as highly selective phosphodiesterase 8A inhibitors.J. Med. Chem.6315852–15863. 10.1021/acs.jmedchem.0c01573
96
JankowskaA.SwierczekA.Chlon-RzepaG.PawlowskiM.WyskaE. (2017). PDE7-selective and dual inhibitors: advances in chemical and biological research.Curr. Med. Chem.24673–700. 10.2174/0929867324666170116125159
97
JarnaginK.ChandaS.CoronadoD.CiaravinoV.ZaneL. T.Guttman-YasskyE.et al (2016). Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis.J. Drugs Dermatol.15390–396.
98
JiangX.PaskindM.WeltzienR.EpsteinP. M. (1998). Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes.Cell Biochem. Biophys.28135–160. 10.1007/bf02737809
99
JimenezJ. L.IniguezM. A.Munoz-FernandezM. A.FresnoM. (2004). Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes.Cell Signal.161363–1373. 10.1016/j.cellsig.2004.04.002
100
JinS. L.BushnikT.LanL.ContiM. (1998). Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene.J. Biol. Chem.27319672–19678. 10.1074/jbc.273.31.19672
101
JinS. L.GoyaS.NakaeS.WangD.BrussM.HouC.et al (2010). Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.J. Allergy Clin. Immunol.1261252–1259.e1212.
102
JohnstoneT. B.SmithK. H.Koziol-WhiteC. J.LiF.KazarianA. G.CorpuzM. L.et al (2017). PDE8 is expressed in human airway smooth muscle and selectively regulates cAMP signaling by beta2AR-AC6.Am. J. Respir Cell Mol. Biol.58530–541. 10.1165/rcmb.2017-0294oc
103
JulianoR. L.ReddigP.AlahariS.EdinM.HoweA.AplinA. (2004). Integrin regulation of cell signalling and motility.Biochem. Soc. Trans.32443–446. 10.1042/bst0320443
104
Kadoshima-YamaokaK.MurakawaM.GotoM.TanakaY.InoueH.MurafujiH.et al (2009). Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte.Int. Immunopharmacol.997–102. 10.1016/j.intimp.2008.10.005
105
KakkarR.RajuR. V.SharmaR. K. (1999). Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1).Cell Mol. Life Sci.551164–1186. 10.1007/s000180050364
106
KambayashiJ.LiuY.SunB.ShakurY.YoshitakeM.CzerwiecF. (2003). Cilostazol as a unique antithrombotic agent.Curr. Pharm. Des.92289–2302. 10.2174/1381612033453910
107
KandaN.WatanabeS. (2001). Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells.Biochem. Pharmacol.62495–507. 10.1016/s0006-2952(01)00688-8
108
KellyM. P. (2018). Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.Cell Signal.42281–291. 10.1016/j.cellsig.2017.11.004
109
KleinR. M.SpoffordL. S.AbelE. V.OrtizA.AplinA. E. (2008). B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization.Mol. Biol. Cell19498–508. 10.1091/mbc.e07-09-0895
110
KobayashiT.GamanumaM.SasakiT.YamashitaY.YuasaK.KoteraJ.et al (2003). Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain.Gene31921–31. 10.1016/s0378-1119(03)00809-6
111
KomasN.MovsesianM.KedovS.DegermanE.BelfrageP.ManganielloV. (1996). “cGMP-inhibited phosphodiesterases (PDE3),” in Phosphodiesterase Inhibitors, edsSchudtC.DentG.RabeK. F. (London: Academic Press), 89–110. 10.1016/b978-012210720-7/50008-3
112
KortumR. L.Rouquette-JazdanianA. K.SamelsonL. E. (2013). Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells.Trends Immunol.34259–268. 10.1016/j.it.2013.02.004
113
KoteraJ.FujishigeK.AkatsukaH.ImaiY.YanakaN.OmoriK. (1998). Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase.J. Biol. Chem.27326982–26990. 10.1074/jbc.273.41.26982
114
LeeJ. W.LeeJ.MoonE. Y. (2014). HeLa human cervical cancer cell migration is inhibited by treatment with dibutyryl-cAMP.Anticancer Res.343447–3455.
115
LeeR.WoldaS.MoonE.EsselstynJ.HertelC.LernerA. (2002). PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.Cell Signal.14277–284. 10.1016/s0898-6568(01)00250-9
116
LernerA.EpsteinP. M. (2006). Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Biochem. J.39321–41. 10.1042/bj20051368
117
LiL.YeeC.BeavoJ. A. (1999). CD3- and CD28-dependent induction of PDE7 required for T cell activation.Science283848–851. 10.1126/science.283.5403.848
118
LimC. J.HanJ.YousefiN.MaY.AmieuxP. S.McknightG. S.et al (2007). Alpha4 integrins are type I cAMP-dependent protein kinase-anchoring proteins.Nat. Cell Biol.9415–421. 10.1038/ncb1561
119
LinC. S.LauA.TuR.LueT. F. (2000). Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum.Biochem. Biophys. Res. Commun.268628–635. 10.1006/bbrc.2000.2187
120
LoughneyK.HillT. R.FlorioV. A.UherL.RosmanG. J.WoldaS. L.et al (1998). Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase.Gene216139–147. 10.1016/s0378-1119(98)00303-5
121
LoughneyK.MartinsT. J.HarrisE. A.SadhuK.HicksJ. B.SonnenburgW. K.et al (1996). Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases.J. Biol. Chem.271796–806. 10.1074/jbc.271.2.796
122
LoughneyK.SnyderP. B.UherL.RosmanG. J.FergusonK.FlorioV. A. (1999). Isolation and characterization of PDE10A, a novel human 3’, 5’-cyclic nucleotide phosphodiesterase.Gene234109–117. 10.1016/s0378-1119(99)00171-7
123
LoughneyK.TaylorJ.FlorioV. A. (2005). 3’,5’-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues.Int. J. Impot. Res.17320–325.
124
LyleK. S.RaaijmakersJ. H.BruinsmaW.BosJ. L.De RooijJ. (2008). cAMP-induced Epac-Rap activation inhibits epithelial cell migration by modulating focal adhesion and leading edge dynamics.Cell. Signal.201104–1116.
125
Maganto-GarciaE.BuD. X.TarrioM. L.AlcaideP.NewtonG.GriffinG. K.et al (2011). Foxp3+-inducible regulatory T cells suppress endothelial activation and leukocyte recruitment.J. Immunol.1873521–3529.
126
ManH. W.SchaferP.WongL. M.PattersonR. T.CorralL. G.RaymonH.et al (2009). Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.J. Med. Chem.521522–1524.
127
ManganielloV. C.SmithC. J.DegermanE.BelfrageP. (1990a). “Cyclic GMP-inhibited cyclic nucleotide phosphodiesterases,” in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edsBeavoJ.HouslayM. D. (West Sussex: John Wiley & Sons Ltd.), 87–115.
128
ManganielloV. C.TanakaT.MurashimaS. (1990b). “Cyclic GMP-stimulated cyclic nucleotide phosphodiesterases,” in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edsBeavoJ.HouslayM. D. (West Sussex: John Wiley & Sons Ltd.), 61–85.
129
MaraisR.LightY.PatersonH. F.MasonC. S.MarshallC. J. (1997). Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases.J. Biol. Chem.2724378–4383.
130
Martin-AlvarezR.Paul-FernandezN.PalomoV.GilC.MartinezA.MengodG. (2017). A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice.J. Chem. Neuroanat.8027–36.
131
MartinsT. J.MumbyM. C.BeavoJ. A. (1982). Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues.J. Biol. Chem.2571973–1979.
132
MauriceD. H. (2013). PDE8A runs interference to limit PKA inhibition of Raf-1.Proc. Natl. Acad. Sci. U.S.A.1106248–6249.
133
MauriceD. H.KeH.AhmadF.WangY.ChungJ.ManganielloV. C. (2014). Advances in targeting cyclic nucleotide phosphodiesterases.Nat. Rev. Drug Discov.13290–314.
134
MeryP. F.PavoineC.PeckerF.FischmeisterR. (1995). Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes.Mol. Pharmacol.48121–130.
135
MichaeliT.BloomT. J.MartinsT.LoughneyK.FergusonK.RiggsM.et al (1993). Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae.J. Biol. Chem.26812925–12932.
136
MichieA. M.LobbanM.MullerT.HarnettM. M.HouslayM. D. (1996). Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.Cell Signal.897–110.
137
MilaraJ.ArmengotM.BanulsP.TenorH.BeumeR.ArtiguesE.et al (2012). Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.Br. J. Pharmacol.1662243–2262.
138
MontesanoR.PepperM. S.Mohle-SteinleinU.RisauW.WagnerE. F.OrciL. (1990). Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene.Cell62435–445.
139
MoonE.LeeR.NearR.WeintraubL.WoldaS.LernerA. (2002). Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.Clin. Cancer Res.8589–595.
140
MosendenR.TaskenK. (2011). Cyclic AMP-mediated immune regulation–overview of mechanisms of action in T cells.Cell Signal.231009–1016.
141
MurataK.SudoT.KameyamaM.FukuokaH.MukaM.DokiY.et al (2000). Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.Clin. Exp. Metastasis18599–604.
142
NakataA.OgawaK.SasakiT.KoyamaN.WadaK.KoteraJ.et al (2002). Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors.Clin. Exp. Immunol.128460–466.
143
NethertonS. J.MauriceD. H. (2005). Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.Mol. Pharmacol.67263–272.
144
NomeT.ThomassenG. O.BruunJ.AhlquistT.BakkenA. C.HoffA. M.et al (2013). Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.Transl. Oncol.6546–553. 10.1593/tlo.13457
145
NorambuenaA.MetzC.VicunaL.SilvaA.PardoE.OyanadelC.et al (2009). Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A down-regulation.J. Biol. Chem.28412670–12679. 10.1074/jbc.m808949200
146
NuedaA.Garcia-RogerN.DomenechT.GodessartN.CardenasA.Santamaria-BabiL. F.et al (2006). Phosphodiesterase 7A1 is expressed in human CD4+ naive T cells at higher levels than in CD4+ memory cells and is not required during their CD3/CD28-dependent activation.Cell Immunol.24231–38. 10.1016/j.cellimm.2006.09.001
147
OrlowskiR. J.O’rourkeK. S.OlorenshawI.HawkinsG. A.MaasS.LaxminarayanaD. (2008). Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes.Immunology125408–419. 10.1111/j.1365-2567.2008.02850.x
148
OuY.ZhengX.GaoY.ShuM.LengT.LiY.et al (2014). Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics.Urol. Oncol.3247.e21–e48.
149
PatruccoE.AlbergineM. S.SantanaL. F.BeavoJ. A. (2010). Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes.J. Mol. Cell Cardiol.49330–333. 10.1016/j.yjmcc.2010.03.016
150
PeterD.JinS. L.ContiM.HatzelmannA.ZittC. (2007). Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D.J. Immunol.1784820–4831. 10.4049/jimmunol.178.8.4820
151
PetteM.MuraroP. A.PetteD. F.DinterH.McfarlandH. F.MartinR. (1999). Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones.J. Neuroimmunol.98147–156.
152
PodzuweitT.NennstielP.MullerA. (1995). Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine.Cell Signal.7733–738. 10.1016/0898-6568(95)00042-n
153
PritchardC. A.HayesL.WojnowskiL.ZimmerA.MaraisR. M.NormanJ. C. (2004). B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts.Mol. Cell. Biol.245937–5952. 10.1128/mcb.24.13.5937-5952.2004
154
PritchardC. A.SamuelsM. L.BoschE.McmahonM. (1995). Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells.Mol. Cell. Biol.156430–6442. 10.1128/mcb.15.11.6430
155
RabeK. F. (2011). Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.Br. J. Pharmacol.16353–67. 10.1111/j.1476-5381.2011.01218.x
156
RedondoM.BreaJ.PerezD. I.SoterasI.ValC.PerezC.et al (2012). Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.J. Med. Chem.553274–3284. 10.1021/jm201720d
157
SasakiT.KoteraJ.YuasaK.OmoriK. (2000). Identification of human PDE7B, a cAMP-specific phosphodiesterase.Biochem. Biophys. Res. Commun.271575–583. 10.1006/bbrc.2000.2661
158
SchaferP. (2012). Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.Biochem. Pharmacol.831583–1590. 10.1016/j.bcp.2012.01.001
159
SchaferP. H.PartonA.GandhiA. K.CaponeL.AdamsM.WuL.et al (2010). Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Br. J. Pharmacol.159842–855. 10.1111/j.1476-5381.2009.00559.x
160
SchettG.SloanV. S.StevensR. M.SchaferP. (2010). Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.Ther. Adv. Musculoskelet Dis.2271–278. 10.1177/1759720x10381432
161
SchettG.WollenhauptJ.PappK.JoosR.RodriguesJ. F.VesseyA. R.et al (2012). Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.Arthritis Rheum.643156–3167. 10.1002/art.34627
162
SharmaR. K.HickieR. A. (1996). “Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1),” in Phosphodiesterase Inhibitors, edsSchudtC.DentG.RabeK. F. (London: Academic Press), 65–80. 10.1016/b978-012210720-7/50006-x
163
ShethS. B.ChagantiK.BastepeM.AjuriaJ.BrennanK.BiradavoluR.et al (1997). Cyclic AMP phosphodiesterases in human lymphocytes.Br. J. Haematol.99784–789. 10.1046/j.1365-2141.1997.4803282.x
164
Shimizu-AlbergineM.Van YserlooB.GolkowskiM. G.OngS. E.BeavoJ. A.BornfeldtK. E. (2016). SCAP/SREBP pathway is required for the full steroidogenic response to cyclic AMP.Proc. Natl. Acad. Sci. U.S.A.113E5685–E5693.
165
SlokaS.MetzL. M.HaderW.StarreveldY.YongV. W. (2013). Reduction of microglial activity in a model of multiple sclerosis by dipyridamole.J. Neuroinflammation10:89.
166
SoderlingS. H.BayugaS. J.BeavoJ. A. (1998a). Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.Proc. Natl. Acad. Sci. U.S.A.958991–8996. 10.1073/pnas.95.15.8991
167
SoderlingS. H.BayugaS. J.BeavoJ. A. (1998b). Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases.J. Biol. Chem.27315553–15558. 10.1074/jbc.273.25.15553
168
SoderlingS. H.BayugaS. J.BeavoJ. A. (1999). Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.Proc. Natl. Acad. Sci. U.S.A.967071–7076. 10.1073/pnas.96.12.7071
169
SoderlingS. H.BeavoJ. A. (2000). Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.Curr. Opin. Cell. Biol.12174–179. 10.1016/s0955-0674(99)00073-3
170
SommerN.MartinR.McfarlandH. F.QuigleyL.CannellaB.RaineC. S.et al (1997). Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.J. Neuroimmunol.7954–61. 10.1016/s0165-5728(97)00111-2
171
SpanoD.MarshallJ. C.MarinoN.De MartinoD.RomanoA.ScoppettuoloM. N.et al (2013). Dipyridamole prevents triple-negative breast-cancer progression.Clin. Exp. Metastasis3047–68. 10.1007/s10585-012-9506-0
172
SriramK.InselP. A. (2018). G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?Mol. Pharmacol.93251–258. 10.1124/mol.117.111062
173
SteinmanL. (2005). Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.Nat. Rev. Drug Discov.4510–518. 10.1038/nrd1752
174
SzczypkaM. (2020). Role of phosphodiesterase 7 (PDE7) in T cell activity. effects of selective PDE7 inhibitors and dual PDE4/7 inhibitors on T cell functions.Int. J. Mol. Sci.21:6118. 10.3390/ijms21176118
175
TakeuchiM.BaichwalV. R. (1995). Induction of the gene encoding mucosal vascular addressin cell adhesion molecule 1 by tumor necrosis factor alpha is mediated by NF-kappa B proteins.Proc. Natl. Acad. Sci. U.S.A.923561–3565. 10.1073/pnas.92.8.3561
176
TaylorK. E.WongQ.LevineD. M.MchughC.LaurieC.DohenyK.et al (2017). Genome-wide association analysis reveals genetic heterogeneity of sjogren’s syndrome according to ancestry.Arthritis Rheumatol.691294–1305. 10.1002/art.40040
177
TenorH.HatzelmannA.BeumeR.LahuG.ZechK.BethkeT. D. (2011). Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.Handb. Exp. Pharmacol.204, 85–119. 10.1007/978-3-642-17969-3_3
178
TenorH.StaniciuL.SchudtC.HatzelmannA.WendelA.DjukanovicR.et al (1995). Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes.Clin. Exp. Allergy25616–624. 10.1111/j.1365-2222.1995.tb01109.x
179
TomW. L.Van SyocM.ChandaS.ZaneL. T. (2016). Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study.Pediatr. Dermatol.33150–159. 10.1111/pde.12780
180
TsaiL. C.BeavoJ. A. (2012). Regulation of adrenal steroidogenesis by the high-affinity phosphodiesterase 8 family.Horm. Metab. Res.44790–794. 10.1055/s-0032-1321861
181
TsaiL. C.ChanG. C.NangleS. N.Shimizu-AlbergineM.JonesG. L.StormD. R.et al (2012). Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay.Genes Brain Behav.11837–847. 10.1111/j.1601-183x.2012.00836.x
182
TsaiL. C.Shimizu-AlbergineM.BeavoJ. A. (2010). The high affinity cAMP-specific phosphodiesterase 8B (PDE8B) controls steroidogenesis in the mouse adrenal gland.Mol. Pharmacol.79639–648. 10.1124/mol.110.069104
183
VaethM.GogishviliT.BoppT.KleinM.Berberich-SiebeltF.GattenloehnerS.et al (2011). Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cell c1 (NFATc1).Proc. Natl. Acad. Sci. U.S.A.1082480–2485. 10.1073/pnas.1009463108
184
VangA. G.BasoleC.DongH.NguyenR. K.HousleyW.GuernseyL.et al (2016). Differential expression and function of PDE8 and PDE4 in effector T cells: implications for PDE8 as a drug target in inflammation.Front. Pharmacol.7:259.
185
VangA. G.Ben-SassonS. Z.DongH.KreamB.DeninnoM. P.ClaffeyM. M.et al (2010). PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.PLoS One5:e12011. 10.1371/journal.pone.0012011
186
VangA. G.HousleyW.DongH.BasoleC.Ben-SassonS. Z.KreamB. E.et al (2013). Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac.Biochem. J.456463–473. 10.1042/bj20130064
187
VictoniT.GleonnecF.LanzettiM.TenorH.ValencaS.PortoL. C.et al (2014). Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.PLoS One9:e85243. 10.1371/journal.pone.0085243
188
VirgilioA.SpanoD.EspositoV.Di DatoV.CitarellaG.MarinoN.et al (2012). Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer.Eur. J. Med. Chem.5741–50. 10.1016/j.ejmech.2012.08.020
189
WallaceD. A.JohnstonL. A.HustonE.MacmasterD.HouslayT. M.CheungY. F.et al (2005). Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene.Mol. Pharmacol.671920–1934.
190
WangC.LinW.PlayaH.SunS.CameronK.BuolamwiniJ. K. (2013a). Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4).Biochem. Pharmacol.861531–1540.
191
WangC.SchwabL. P.FanM.SeagrovesT. N.BuolamwiniJ. K. (2013b). Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer.Cancer Prev. Res. (Phila)6437–447.
192
WangH.YanZ.YangS.CaiJ.RobinsonH.KeH. (2008). Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.Biochemistry4712760–12768.
193
WangJ. H.SharmaR. K.MooibroekM. J. (1990). “Calmodulin-stimulated cyclic nucleotide phosphodiesterases,” in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edsBeavoJ.HouslayM. D. (West Sussex: John Wiley & Sons Ltd), 19–59.
194
WangP.WuP.EganR. W.BillahM. M. (2000). Cloning, characterization, and tissue distribution of mouse phosphodiesterase 7A1.Biochem. Biophys. Res. Commun.2761271–1277.
195
WangP.WuP.EganR. W.BillahM. M. (2003). Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants.Gene31415–27.
196
WangP.WuP.MyersJ. G.StamfordA.EganR. W.BillahM. M. (2001). Characterization of human, dog and rabbit corpus cavernosum type 5 phosphodiesterases.Life Sci.681977–1987.
197
WangT.SheppardJ. R.FokerJ. E. (1978). Rise and fall of cyclic AMP required for onset of lymphocyte DNA synthesis.Science201155–157.
198
WeberC. K.SlupskyJ. R.HerrmannC.SchulerM.RappU. R.BlockC. (2000). Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes.Oncogene19169–176.
199
WeeksJ. L.ZoraghiR.BeasleyA.SekharK. R.FrancisS. H.CorbinJ. D. (2005). High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.Int. J. Impot. Res.175–9.
200
WehbiV. L.TaskenK. (2016). Molecular mechanisms for cAMP-mediated immunoregulation in T cells–role of anchored protein kinase A signaling units.Front. Immunol.7:222.
201
WeisW. I.KobilkaB. K. (2018). The molecular basis of G protein-coupled receptor activation.Annu. Rev. Biochem.87897–919.
202
WittmannM.HelliwellP. S. (2013). Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.Dermatol. Ther. (Heidelb)31–15.
203
WojnowskiL.StancatoL. F.LarnerA. C.RappU. R.ZimmerA. (2000). Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis.Mech. Dev.9197–104.
204
XuC.WymanA. R.AlaameryM. A.ArguetaS. A.IveyF. D.MeyersJ. A.et al (2016). Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes.Int. Immunopharmacol.38223–232.
205
YanC.ZhaoA. Z.BentleyJ. K.LoughneyK.FergusonK.BeavoJ. A. (1995). Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons.Proc. Natl. Acad. Sci. U.S.A.929677–9681.
206
YangG.McintyreK. W.TownsendR. M.ShenH. H.PittsW. J.DoddJ. H.et al (2003). Phosphodiesterase 7A-deficient mice have functional T cells.J. Immunol.1716414–6420.
207
YednockT. A.CannonC.FritzL. C.Sanchez-MadridF.SteinmanL.KarinN. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.Nature35663–66.
208
YuJ.WoldaS. L.FrazierA. L.FlorioV. A.MartinsT. J.SnyderP. B.et al (1997). Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1.Cell Signal.9519–529.
209
YuasaK.KoteraJ.FujishigeK.MichibataH.SasakiT.OmoriK. (2000). Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression.J. Biol. Chem.27531469–31479.
210
ZaneL. T.ChandaS.JarnaginK.NelsonD. B.SpelmanL.GoldL. S. (2016a). Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.Immunotherapy8853–866.
211
ZaneL. T.KircikL.CallR.TschenE.DraelosZ. D.ChandaS.et al (2016b). Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: A phase 1b, Open-Label, maximal-use systemic exposure study.Pediatr. Dermatol.33380–387.
212
ZhaoA. Z.YanC.SonnenburgW. K.BeavoJ. A. (1997). Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions.Adv. Second Messenger Phosphoprotein Res.31237–251.
213
ZimmermanN. P.RoyI.HauserA. D.WilsonJ. M.WilliamsC. L.DwinellM. B. (2015). Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells.Mol. Carcinog.54203–215.
Summary
Keywords
cAMP, phosphodiesterase, PDE8, Raf-1 kinase, T cell motility, leukocyte recruitment, inflammation, integrin adhesion
Citation
Epstein PM, Basole C and Brocke S (2021) The Role of PDE8 in T Cell Recruitment and Function in Inflammation. Front. Cell Dev. Biol. 9:636778. doi: 10.3389/fcell.2021.636778
Received
02 December 2020
Accepted
29 March 2021
Published
16 April 2021
Volume
9 - 2021
Edited by
Xunbin Wei, Peking University, China
Reviewed by
Lai Wen, La Jolla Institute for Immunology (LJI), United States; Clive P. Page, King’s College London, United Kingdom; Donald H. Maurice, Queen’s University, Canada; Martina Schmidt, University of Groningen, Netherlands
Updates
Copyright
© 2021 Epstein, Basole and Brocke.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stefan Brocke, sbrocke@uchc.edu
This article was submitted to Cell Adhesion and Migration, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.